Welcome to Tern Therapeutics, where we’re pioneering a new approach to the development of one-time gene therapy treatments for rare disease.

 

We’re driven to deliver transformative treatments with urgency to those living around the world with rare diseases.

 

Our lead candidate, TTX-381, is currently in clinical testing for the treatment of ocular manifestations of CLN2, a form of Batten disease.